Whole Genome MBD-seq reveals different CpG methylation patterns in Azacytidine-treated Juvenile Myelomonocytic Leukaemia (JMML) patients.

Pier Paolo LeonciniPatrizia VitulloFrancesca Di FlorioValeria ToccoMaria Giuseppina CefaloAngela PitisciKatia GirardiCharlotte NiemeyerFranco LocatelliAlice Bertaina

Published in: British journal of haematology (2017)

Keyphrases

end stage renal disease
newly diagnosed
dna methylation
genome wide
ejection fraction
chronic kidney disease
prognostic factors
single cell
patient reported outcomes
rna seq